Proteome Sciences plc

LSE PRM.L

Proteome Sciences plc Price to Earnings Ratio (P/E) on January 14, 2025: -5.00

Proteome Sciences plc Price to Earnings Ratio (P/E) is -5.00 on January 14, 2025, a 8.35% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Proteome Sciences plc 52-week high Price to Earnings Ratio (P/E) is -2.64 on December 20, 2024, which is 47.16% above the current Price to Earnings Ratio (P/E).
  • Proteome Sciences plc 52-week low Price to Earnings Ratio (P/E) is -5.91 on January 19, 2024, which is -18.30% below the current Price to Earnings Ratio (P/E).
  • Proteome Sciences plc average Price to Earnings Ratio (P/E) for the last 52 weeks is -4.21.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
LSE: PRM.L

Proteome Sciences plc

CEO Dr. Mariola Sohngen
IPO Date Oct. 3, 1995
Location United Kingdom
Headquarters Coveham House
Employees 35
Sector Health Care
Industries
Description

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. It also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers. In addition, the company offers bioinformatics tools, including Proteome Discoverer for peptide sequence and TMT quantitation; SQuaT,CalDIT, and DIANA for normalized quantitative values and functional annotation at peptide and protein level; FeaST for visualization of data quality, class identifier model, and biomarker candidate lists; and FAT for identification of biological processes and cellular components showing variance. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.

Similar companies

OXB.L

Oxford Biomedica plc

USD 4.79

-4.31%

IMM.L

ImmuPharma plc

USD 0.04

-14.59%

SCLP.L

Scancell Holdings plc

USD 0.11

-4.08%

StockViz Staff

January 15, 2025

Any question? Send us an email